This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Believe HashiCorp, Inc. (HCP) Could Rally 56%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for HashiCorp, Inc. (HCP) points to a 56.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why Is Coupa Software (COUP) Down 2.3% Since Last Earnings Report?
by Zacks Equity Research
Coupa Software (COUP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts See a 58% Upside in HashiCorp, Inc. (HCP): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 57.8% in HashiCorp, Inc. (HCP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
HCP Tops Q3 FFO Estimate, Changes Name to Healthpeak Properties
by Zacks Equity Research
HCP, now renamed Healthpeak Properties, puts up an impressive show in third-quarter 2019 on the back of growth in the life-science and medical-office segments' net operating income.
MGP vs. HCP: Which Stock Is the Better Value Option?
by Zacks Equity Research
MGP vs. HCP: Which Stock Is the Better Value Option?
HCP (HCP) Q3 FFO and Revenues Surpass Estimates
by Zacks Equity Research
HCP (HCP) delivered FFO and revenue surprises of 2.33% and 5.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Alexandria (ARE) Q3 FFO Meets Estimates, Rental Rate Grows
by Zacks Equity Research
Alexandria Real Estate Equities' (ARE) Q3 results reflect decent internal and external growth, as well as continued strong leasing activity and rental-rate growth in the quarter.
Will Growth in Seniors Housing Market Aid HCP's Q3 Earnings?
by Zacks Equity Research
While HCP's Q3 results will likely reflect benefits of higher occupancy in the U.S. seniors housing market, a decline in income from direct financing lease might have impacted its revenue growth.
HCP Announces Strategic Portfolio Trades With Brookdale
by Zacks Equity Research
HCP's mutually-beneficial agreement with Brookdale reduces the operator's concentration in the company's portfolio to 8% and enables transitions to Life Care Services under a highly-incentivized contract.
Encouraging Near-Term Outlook for Equity REIT Stocks
by Moumita Chattopadhyay
With market dynamics of individual asset categories playing crucial roles in determining performance and economic indicators looking decent, REIT stocks have scope to excel.
HCP to Buy Life Science Asset, Boost West Cambridge Cluster
by Zacks Equity Research
Delivering on its strategy to expand presence in the Boston region, HCP will acquire a trophy life science property -- 35 CambridgePark Drive -- for $332.5 million.
Public Storage (PSA) Unveils Storage Units in Murfreesboro
by Zacks Equity Research
The latest unveiling of Public Storage's (PSA) storage units in Murfreesboro comes as part of the company's effort to expand in this region which has been witnessing rapid growth of the neighborhood.
Boston Properties Issues $700M Senior Notes, Refinances Debt
by Zacks Equity Research
Boston Properties (BXP) will redeem its outstanding 5.625% senior notes due in 2020 by using proceed raised from sale of 2.9% senior notes, which will likely result in interest saving.
Medical Properties Cheers Investors With 4% Hike in Dividend
by Zacks Equity Research
Medical Properties' (MPW) recent quarterly dividend hike indicates the sixth consecutive year of such increase.
Is it Apt to Hold Welltower (WELL) in Your Portfolio Now?
by Zacks Equity Research
While Welltower (WELL) is aimed at fortifying the senior housing portfolio through strategic investments, near-term earnings dilution from asset sales remains a concern.
4 Reasons Why You Should Add HCP to Your Portfolio Right Now
by Zacks Equity Research
HCP's efforts to expand its medical office and life-science portfolio, a diversified and high-quality portfolio and favorable demographic trends make it an attractive pick.
HCP Surpasses Q2 FFO & Revenue Estimates, Raises Outlook
by Zacks Equity Research
HCP witnesses rise in revenues and net operating income in the second quarter of 2019.
HCP (HCP) Q2 FFO and Revenues Beat Estimates
by Zacks Equity Research
HCP (HCP) delivered FFO and revenue surprises of 2.33% and 9.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Key Factors Setting the Tone for HCP This Earnings Season
by Zacks Equity Research
Focus on life-science and MOB portfolio will likely enable HCP to witness decent growth in Q2. However, prevalent challenges in the senior housing market are a spoilsport.
Ventas (VTR) to Buy Seniors Housing Portfolio Worth $1.8B
by Zacks Equity Research
Acquisition of seniors housing portfolio valued at $1.8 billion, including construction in progress, will likely help Ventas (VTR) in diversifying its assets, business model and operator base.
Why Is HCP (HCP) Up 2.8% Since Last Earnings Report?
by Zacks Equity Research
HCP (HCP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HCP Amends and Restates Credit Facility, Boosts Strength
by Zacks Equity Research
HCP's amended and restated credit helps increase the size of the facility, extend the maturity date, lower the borrowing costs and boost financial flexibility.
CORR vs. HCP: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CORR vs. HCP: Which Stock Is the Better Value Option?
HCP's Q1 FFO Surpasses, Revenues Miss Estimates, NOI Up
by Zacks Equity Research
HCP's first-quarter 2019 results indicate decent performance of the company's life-science and medical-office segments. Yet, tepid performance of seniors-housing portfolio remains a drag.
HCP (HCP) Q1 FFO Beat Estimates
by Zacks Equity Research
HCP (HCP) delivered FFO and revenue surprises of 2.33% and -1.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?